Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response in Pneumococcal Pneumonia vs Vaccination
NCT01402245Phase 4Completed
- Sponsor
- Helsinki University Hospital
- Start
- Jan 2005
- Primary completion
- Jun 2010
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label trial of 23-valent pneumococcal polysaccharide vaccine and pneumococcal 7-valent conjugate vaccine in Pneumococcal pneumonia (PP), sponsored by Helsinki University Hospital. Primary endpoint: Expression of homing receptors on circulating plasmablasts at Day 10. Started Jan 2005; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccinepneumococcal 7-valent conjugate vaccine
03
Conditions
Pneumococcal pneumonia (PP)
Beyond the preview
Go deeper on NCT01402245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01402245.